The Mount Sinai CCOP (MSCCOP) is comprised of one component and four affiliate members;It will celebrate its 26th year as an NCI-supported program in 2013. It has been a consistent leader in minority accrual nationwide with particular emphasis on the Hispanic population. The MSCCOP seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research. The ongoing mission of the MSCCOP is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally we offer ongoing education about cancer and the NCI clinical trials program to both health care professionals and the community. This grant application encompasses and articulates an ongoing vision for the MSCCOP with goals that include: (a) increased patient access and accrual to cancer treatment, prevention and control protocols;(b) increased accrual of minorities, women, and underserved populations;(c) establishment of a stronger and more cohesive affiliate network;(d) strengthened relationships with and contributions to affiliated research bases;(e) maintenance of high-quality data management. Key strategies to increase patient access and accrual to research protocols include expanding participation in symptom management studies, strengthening partnerships with community organizations serving the Hispanic community, increasing participation with newly-consolidated NCI cooperative groups, and improving systems and services that will benefit affiliate institutions.
The Community Clinical Oncology Program (CCOP) links community cancer specialists, primary care physicians, and other health care professionals to the NCI-supported Cooperative Groups and Cancer Centers to conduct NCI-approved cancer treatment, prevention, and control clinical trials. The MSCCOP is the only CCOP in south Florida serving adults and is a major resource for the Hispanic community.
|Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9|
|Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86|
|Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9|
|Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7|
|Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7|
|Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38|
|Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89|
|Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21|
|Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98|
|Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20|
Showing the most recent 10 out of 45 publications